KR980000445A - Recognition enhancer method - Google Patents

Recognition enhancer method Download PDF

Info

Publication number
KR980000445A
KR980000445A KR1019970025073A KR19970025073A KR980000445A KR 980000445 A KR980000445 A KR 980000445A KR 1019970025073 A KR1019970025073 A KR 1019970025073A KR 19970025073 A KR19970025073 A KR 19970025073A KR 980000445 A KR980000445 A KR 980000445A
Authority
KR
South Korea
Prior art keywords
pharmaceutically acceptable
acceptable salt
treatment
acetylcholinesterase inhibitor
darfenacin
Prior art date
Application number
KR1019970025073A
Other languages
Korean (ko)
Inventor
마이클 존 알렌
브리안 프랑크 존슨
브리안 로버트 리커
로버트 마이클 왈리스
Original Assignee
무어 제임스 더블유
화이자 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 무어 제임스 더블유, 화이자 인코포레이티드 filed Critical 무어 제임스 더블유
Publication of KR980000445A publication Critical patent/KR980000445A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01007—Acetylcholinesterase (3.1.1.7)

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Control Of Eletrric Generators (AREA)
  • Soil Working Implements (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Chemical Treatment Of Metals (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

다리페나신 및 그의 약학적으로 허용가능한 염은 인식 장애의 치료에 유용하다.Dalifenacin and its pharmaceutically acceptable salts are useful for the treatment of cognitive disorders.

본 발명은 또한 다리페나신 또는 그의 약학적으로 허용가능한 염과 아세틸콜린에스터레이즈 억제제와의 혼합된 제제의 인식 장애의 치료에서의 용도를 개시한다.The present invention also discloses the use of a mixed formulation of darfenacin or a pharmaceutically acceptable salt thereof with an acetylcholinesterase inhibitor in the treatment of cognitive disorders.

Description

인식 증강 방법Recognition enhancer method

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

Claims (6)

다리페나신 또는 그의 약학적으로 허용가능한 염, 및 약학적으로 허용가능한 아쥬방트, 회석제 또는 담체를 포함하는 인식 장애 치료용 약제.A medicament for the treatment of cognitive disorders comprising darfenacin or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable adjuvant, diluent or carrier. 제1항에 있어서, 아세틸콜린에스터레이즈 억제제를 더욱 포함하는 약제.The agent of claim 1, further comprising an acetylcholinesterase inhibitor. 제2항에 있어서, 아세틸콜린에스터레이즈 억제제가 도네피질 또는 그의 약학적으로 허용가능한 염인 약제.The medicament according to claim 2, wherein the acetylcholinesterase inhibitor is donepezil or a pharmaceutically acceptable salt thereof. 제1항 내지 제3항 중 어느 한 항에 있어서, 인식 장애가 알쯔하이며 병에 기인한 약제.The agent according to any one of claims 1 to 3, wherein the cognitive disorder is Alzheimer's and is caused by a disease. 제1항 내지 제3항 중 어느 한 항에 있어서, 인식 장애가 노령과 연관된 기억 장애에 기인한 약제.The medicament according to any one of claims 1 to 3, wherein the cognitive disorder is due to a memory disorder associated with old age. 인식 장애의 치료시 동시에, 개별적으로 또는 순차적으로 사용되는 혼합된 제제로서 다리페나신 또는 그의 약학적으로 허용가능한 염 및 아세틸콜린에스터레이즈 억제제를 함유하는 약품.A pharmaceutical product containing darfenacin or a pharmaceutically acceptable salt thereof and an acetylcholinesterase inhibitor as a mixed preparation used simultaneously, individually or sequentially in the treatment of a cognitive disorder. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019970025073A 1996-06-18 1997-06-17 Recognition enhancer method KR980000445A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9612710.5A GB9612710D0 (en) 1996-06-18 1996-06-18 Method of treatment
GB9612710.5 1996-06-18

Publications (1)

Publication Number Publication Date
KR980000445A true KR980000445A (en) 1998-03-30

Family

ID=10795468

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019970025073A KR980000445A (en) 1996-06-18 1997-06-17 Recognition enhancer method

Country Status (15)

Country Link
US (1) US5837724A (en)
EP (1) EP0813870B1 (en)
JP (1) JP3453493B2 (en)
KR (1) KR980000445A (en)
AT (1) ATE243514T1 (en)
AU (1) AU2495697A (en)
CA (1) CA2208111C (en)
DE (1) DE69722999T2 (en)
DK (1) DK0813870T3 (en)
ES (1) ES2197972T3 (en)
GB (1) GB9612710D0 (en)
HU (1) HUP9701060A3 (en)
IL (1) IL121036A0 (en)
PT (1) PT813870E (en)
ZA (1) ZA975311B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19707655A1 (en) * 1997-02-26 1998-08-27 Hoechst Ag Combination preparation for use in dementia
US20040209849A1 (en) * 1998-11-27 2004-10-21 Sanochemia Pharmazeutika Aktiengesellschaft Use of effectors of the central cholinergic nervous system for treatment of delirium
GB0207104D0 (en) * 2002-03-26 2002-05-08 Pfizer Ltd Stable hydrate of a muscarinic receptor antagonist
JP4767842B2 (en) * 2003-04-01 2011-09-07 セラヴァンス， インコーポレーテッド Diarylmethyl compounds and related compounds having β2 adrenergic receptor agonist activity and muscarinic receptor antagonist activity
MX347901B (en) 2008-03-27 2017-05-18 Chase Pharmaceuticals Corp Use and composition for treating dementia.
US10265311B2 (en) 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
WO2011011060A1 (en) 2009-07-22 2011-01-27 Puretech Ventures Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
JP7079777B2 (en) * 2017-06-01 2022-06-02 エーザイ・アール・アンド・ディー・マネジメント株式会社 Dementia treatment agent by combined use of pyrazoloquinoline derivative and donepezil
IL281809B (en) 2018-09-28 2022-09-01 Karuna Therapeutics Inc Compositions and methods for treating disorders ameliorated by muscarinic receptor activation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5233053A (en) * 1989-03-17 1993-08-03 Pfizer Inc. Pyrrolidine derivatives
GB9400600D0 (en) * 1994-01-14 1994-03-09 Pfizer Ltd Treatment of motion seckness

Also Published As

Publication number Publication date
US5837724A (en) 1998-11-17
CA2208111A1 (en) 1997-12-18
IL121036A0 (en) 1997-11-20
AU2495697A (en) 1998-01-08
GB9612710D0 (en) 1996-08-21
ZA975311B (en) 1998-12-17
JPH1059848A (en) 1998-03-03
HU9701060D0 (en) 1997-08-28
DE69722999T2 (en) 2003-12-18
EP0813870B1 (en) 2003-06-25
DK0813870T3 (en) 2003-08-18
EP0813870A1 (en) 1997-12-29
ATE243514T1 (en) 2003-07-15
JP3453493B2 (en) 2003-10-06
ES2197972T3 (en) 2004-01-16
CA2208111C (en) 2002-10-15
DE69722999D1 (en) 2003-07-31
HUP9701060A2 (en) 1998-12-28
PT813870E (en) 2003-10-31
HUP9701060A3 (en) 1999-03-29

Similar Documents

Publication Publication Date Title
FI961809A0 (en) Novel (R) -5-carbamoyl-8-fluoro-3-N, N-disubstituted amino 3,4-dihydro-2H-1-benzopyrans
KR930012022A (en) Modafinil for brain tissue protection
KR920019342A (en) Bone Disease Treatment
HUT50786A (en) Process for producing new condensed heterocyclic compounds and pharmaceutical compositions containing them as active components
DK0562512T3 (en) Sulfonamidocarbonylpyridine-2-carboxylic acid amides as well as their use as drugs
FI903153A0 (en) 11B-ARYL-4-ESTRENER, FOERFARANDE FOER DERAS FRAMSTAELLNING SAMT DERAS ANVAENDNING SOM LAEKEMEDEL.
KR950031060A (en) Pharmaceutical composition for the treatment of osteoporosis
DK0422485T3 (en) Quinolone carboxylic acid derivatives, methods for their preparation and their use as antivirals
KR980000445A (en) Recognition enhancer method
MD1560F2 (en) Cyclic compounds, pharmaceutical compositions on base thereof and methods of treatment of infections or diseases provoked by retroviruses.
RU94040886A (en) Use of melatonine derivatives for sleep disturbance treatment, pharmaceutical composition
HUT50325A (en) Process for producing bisphenylalkyl piperazine derivatives and pharmaceutical compositions comprising same as active ingredient
HUP0300863A2 (en) N-(3,5-dichloro-2-methoxyphenyl)-4-methoxy-3-piperazin-1-yl-benzenesulfonamide, process for producing it and pharmaceutical composition containing it
KR930023338A (en) Depo formulation
DE69623641T2 (en) TOPICAL FOAMING MEDICINE FOR THE TREATMENT OF SKIN DISEASES CAUSED BY PITYROSPORUM OVALE
FR2722689B1 (en) NOVEL COMBINATION PRODUCT COMPRISING AN ANTIFUNGAL AGENT AND CROTAMITON AS A POTENTIALIZER OF THE ACTIVITY OF THE ANTIFUNGAL AGENT, AND DERMATOLOGICAL AND / OR COSMETIC COMPOSITIONS COMPRISING THE SAME
NO975790D0 (en) Use of allylamine derivatives, such as terbinafine, in the manufacture of a medicament for the treatment of helicobacter pylori infection-associated diseases
KR940021524A (en) 1,2,5,6-tetrahydropyridine derivatives, preparation method thereof and use thereof in treatment
MXPA05009763A (en) 2-(butyl-1 -sulfonylamino) -n-[1(r) -(6-methoxy -pyridin -3-yl)- propyl] -benzamid, the use thereof in the form of drug an pharmaceutical preparations containing said compound.
RU94036762A (en) Heteroarylpiperidines, method of their synthesis, intermediate compounds at synthesis and pharmaceutical composition
KR960003718A (en) Use of Ifenprodil and its Diastereomers for the Preparation of Medicines Useful for the Treatment of Peripheral and Central Neurodegenerative Diseases
ES2190499T3 (en) USE OF BRADIQUININE ANTAGONISTS FOR THE PREPARATION OF MEDICINES FOR THE TREATMENT AND PREVENTION OF ALZHEIMER'S DISEASE.
BR9607841A (en) Method for the preparation of anhydroeggonine esters
CA2154485A1 (en) Pharmaceutical composition containing 5-morpholinomethyl-3-(4-chlorobenzylideneamine)-2-oxazolidinone and its use for the treatment of cns disorders
ATE111461T1 (en) N-((2-THENOYLMERKAPTO-3-METHYL)-BUTANOYL>- HOMOCYSTEIN THIOLACTONE, PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application